Familial Hypercholesterolemia

Althera announced the FDA approved its rosuvastatin/ezetimibe tablets as an adjunct to diet for treatment of elevated LDL in adults with primary nonfamilial hyperlipidemia or homozygous familial hypercholesterolemia.

Regeneron announced the FDA has approved evinacumab for treatment of patients aged 12 years or older with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering therapies.

Racial/ethnic disparities are prevalent in today’s familial hypercholesterolemia research, and care and equitable representation is urgently needed, according to a perspective published in Circulation: Cardiovascular Quality and Outcomes.

Healio and Cardiology Today have aggregated a list of the most-read news on racial disparities in CV health and care.

Race alone may not explain disparities in risk for atherosclerotic CVD among patients with familial hypercholesterolemia, according to data presented at the virtual National Lipid Association Scientific Sessions.

Statin therapy at a young age is safe and effective in preventing future adverse CV events in patients at increased atherosclerotic risk, but girls and women may require counseling for pregnancy planning, a speaker reported.

Children with heterozygous familial hypercholesterolemia who received monthly injections of evolocumab had greater reductions in LDL and other lipid variables at 24 weeks compared with placebo, according to results of the HAUSER-RCT trial.

A machine learning algorithm to identify patients with familial hypercholesterolemia was successfully implemented in a large health care system, according to a presentation.

LDL reduction with alirocumab (Praluent, Sanofi/Regeneron) every 2 weeks vs. placebo in patients with homozygous familial hypercholesterolemia.

Three machine learning approaches outperformed the Dutch Lipid Score to diagnose patients with genetic mutations that cause familial hypercholesterolemia, according to a study published in the European Journal of Preventive Cardiology.